RVNC
Revance Therapeutics, Inc. [RVNC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RVNC Stock Summary
Top 10 Correlated ETFs
RVNC
Top 10 Correlated Stocks
RVNC
In the News
Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn
Revance Therapeutics, Inc. stock has fallen by half in the past six months, despite impressive sales growth, prompting speculation on whether it is now a good buy. The recent DAXXIFY launch seems to be proceeding well, but quarterly cash burn remains an issue as Revance challenges Botox in this space. Analysts have mixed opinions on the stock, with some reiterating buy ratings and others issuing neutral ratings.
3 Healthcare Stocks to Sell in September Before They Crash & Burn
The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA approval and positive results for therapies, pharmaceuticals, and trials greatly influences the outlook for companies, especially ones with small market cap share price.
3 Very Oversold Biotech Stocks to Buy Right Now
After I spent many years following Wall Street, there are a few characteristics about the “big money” that stand out for me. One of these traits is that many if not most large investors are very reluctant to buy stocks that have a 60%-80% chance of climbing a great deal in the long term but a 10%-15% chance of plunging in the short-to-medium term.
Revance shares gain 8% after FDA approval of cervical dystonia treatment
Shares of Revance Therapeutics Inc. RVNC, -3.81% gained 8% premarket on Monday after the U.S. Food and Drug Administration approved the biotech company's Daxxify injection for treatment of cervical dystonia in adults. Cervical dystonia is a chronic disease that causes painful, involuntary neck muscle contractions and affects about 60,000 people in the U.S. Daxxify, a Botox competitor, previously received FDA approval late last year for the temporary improvement of frown lines.
Revance's Botox rival gets FDA approval for painful neck muscle condition
The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's Botox.
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates
Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.88 per share a year ago.
After Plunging -17.93% in 4 Weeks, Here's Why the Trend Might Reverse for Revance Therapeutics, Inc. (RVNC)
Revance Therapeutics, Inc. (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
7 Healthcare Stocks to Make You the Millionaire Next Door
Investing in healthcare stocks can be a wise decision for those looking to become wealthy in the long term. Some of the best healthcare stocks to buy are firms that are developing highly effective drugs for prevalent diseases for which there are no real effective treatments.
This Botox Rival Has Investors Smiling With A 100% Gain This Year. The Stock Broke Out Today.
Revance Therapeutics, a biotech stock, is at a 52-week high and reports earnings Tuesday. Their frown line treatment lasts longer than Botox.
Top 4 Stocks Set to Beat on Earnings Today After Market Closes
We have narrowed our search to four stocks that are set to report earnings results today after market closes. These are: WYNN, CELH, RVNC and IAC.
RVNC Financial details
RVNC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.1 | 0.01 | 0.26 | 1.15 | 1.82 | |
| Net income per share | -3.94 | -3.59 | -4.86 | -4.25 | -4.9 | |
| Operating cash flow per share | -2.88 | -2.44 | -3.08 | -3.28 | -2.66 | |
| Free cash flow per share | -3.08 | -2.52 | -3.15 | -3.55 | -2.98 | |
| Cash per share | 4.86 | 6.68 | 7.52 | 3.33 | 4.69 | |
| Book value per share | 4.03 | 5.19 | 6.45 | 1.01 | 0.17 | |
| Tangible book value per share | 4.03 | 5.19 | 2.69 | -1.98 | -1.26 | |
| Share holders equity per share | 4.03 | 5.19 | 6.45 | 1.01 | 0.17 | |
| Interest debt per share | 0.4 | 0.68 | 3.92 | 4.9 | 5.98 | |
| Market cap | 728.13M | 705.37M | 1.64B | 1.1B | 1.34B | |
| Enterprise value | 654.88M | 563.55M | 1.52B | 1.32B | 1.65B | |
| P/E ratio | -5.11 | -4.52 | -5.83 | -3.84 | -3.77 | |
| Price to sales ratio | 195.26 | 1.71K | 107.27 | 14.16 | 10.13 | |
| POCF ratio | -6.98 | -6.64 | -9.21 | -4.97 | -6.94 | |
| PFCF ratio | -6.54 | -6.45 | -9 | -4.6 | -6.2 | |
| P/B Ratio | 5 | 3.13 | 4.39 | 16.09 | 106.53 | |
| PTB ratio | 5 | 3.13 | 4.39 | 16.09 | 106.53 | |
| EV to sales | 175.62 | 1.36K | 99.35 | 16.91 | 12.46 | |
| Enterprise value over EBITDA | -4.7 | -3.54 | -5.78 | -5.04 | -6.84 | |
| EV to operating cash flow | -6.28 | -5.31 | -8.53 | -5.94 | -8.53 | |
| EV to free cash flow | -5.88 | -5.15 | -8.33 | -5.49 | -7.63 | |
| Earnings yield | -0.2 | -0.22 | -0.17 | -0.26 | -0.27 | |
| Free cash flow yield | -0.15 | -0.16 | -0.11 | -0.22 | -0.16 | |
| Debt to equity | 0.1 | 0.13 | 0.57 | 4.74 | 33.21 | |
| Debt to assets | 0.06 | 0.09 | 0.29 | 0.61 | 0.72 | |
| Net debt to EBITDA | 0.53 | 0.89 | 0.46 | -0.82 | -1.28 | |
| Current ratio | 6.5 | 7.24 | 7.38 | 3.66 | 4.95 | |
| Interest coverage | -3.24K | 0 | -18.03 | -43.79 | -16.52 | |
| Income quality | 0.73 | 0.67 | 0.63 | 0.79 | 0.54 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 14.44 | 150.15 | 9.77 | 0.36 | 0.03 | |
| Research and developement to revenue | 24.81 | 249.06 | 8.21 | 1.49 | 0.76 | |
| Intangibles to total assets | 0 | 0 | 0.3 | 0.38 | 0.18 | |
| Capex to operating cash flow | 0.07 | 0.03 | 0.02 | 0.08 | 0.12 | |
| Capex to revenue | -1.9 | -7.84 | -0.28 | -0.23 | -0.17 | |
| Capex to depreciation | -4.11 | -1.11 | -0.41 | -0.91 | -0.59 | |
| Stock based compensation to revenue | 4.36 | 43.39 | 2.38 | 0.56 | 0.39 | |
| Graham number | 18.9 | 20.48 | 26.57 | 9.85 | 4.37 | |
| ROIC | -0.91 | -0.57 | -0.44 | -0.64 | -0.58 | |
| Return on tangible assets | -0.63 | -0.46 | -0.56 | -0.87 | -0.75 | |
| Graham Net | 3.19 | 4.03 | 1.64 | -3.41 | -2.9 | |
| Working capital | 175.95M | 255.62M | 389.04M | 178.83M | 299.05M | |
| Tangible asset value | 145.62M | 225.49M | 155.98M | -133.83M | -91.58M | |
| Net current asset value | 127.2M | 181.81M | 104.07M | -216.58M | -194.57M | |
| Invested capital | 0.1 | 0.13 | 0.57 | 4.74 | 33.21 | |
| Average receivables | 13.52M | 13.5M | 914.5K | 2.59M | 7.34M | |
| Average payables | 7.62M | 8.22M | 10.33M | 11.63M | 7.57M | |
| Average inventory | 0 | 0 | 2.94M | 8.02M | 14.24M | |
| Days sales outstanding | 2.64K | 0 | 43.56 | 15.71 | 31.22 | |
| Days payables outstanding | 0 | 0 | 968.72 | 165.32 | 32.12 | |
| Days of inventory on hand | 0 | 0 | 449.73 | 158.32 | 129.46 | |
| Receivables turnover | 0.14 | 0 | 8.38 | 23.24 | 11.69 | |
| Payables turnover | 0 | 0 | 0.38 | 2.21 | 11.37 | |
| Inventory turnover | 0 | 0 | 0.81 | 2.31 | 2.82 | |
| ROE | -0.98 | -0.69 | -0.75 | -4.19 | -28.29 | |
| Capex per share | -0.2 | -0.07 | -0.07 | -0.27 | -0.32 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.4 | 0.4 | 0.62 | 0.61 | 0.69 | |
| Net income per share | -0.88 | -1.17 | -1.8 | -0.81 | -0.8 | |
| Operating cash flow per share | -0.63 | -0.8 | -0.38 | -0.86 | -0.64 | |
| Free cash flow per share | -0.71 | -0.83 | -0.64 | -0.87 | -0.63 | |
| Cash per share | 3.34 | 5.24 | 4.25 | 3.38 | 3.82 | |
| Book value per share | -0.04 | 2.02 | 0.16 | -0.33 | 0.32 | |
| Tangible book value per share | -2.81 | -0.61 | -1.14 | -1.66 | -0.94 | |
| Share holders equity per share | -0.04 | 2.02 | 0.16 | -0.33 | 0.32 | |
| Interest debt per share | 6.3 | 6.02 | 5.27 | 5.43 | 5.22 | |
| Market cap | 968.25M | 1.95B | 1.48B | 2.61B | 2.12B | |
| Enterprise value | 1.34B | 2.27B | 1.79B | 2.91B | 2.41B | |
| P/E ratio | -3.94 | -5.75 | -2.56 | -9.89 | -7.87 | |
| Price to sales ratio | 34.13 | 67.19 | 29.63 | 52.98 | 36.43 | |
| POCF ratio | -21.89 | -33.69 | -49.01 | -37.6 | -39.68 | |
| PFCF ratio | -19.51 | -32.61 | -28.85 | -37.14 | -39.88 | |
| P/B Ratio | -368.02 | 13.38 | 117.39 | -97.98 | 79.07 | |
| PTB ratio | -368.02 | 13.38 | 117.39 | -97.98 | 79.07 | |
| EV to sales | 47.11 | 78.34 | 35.83 | 59.04 | 41.44 | |
| Enterprise value over EBITDA | -26.26 | -33.72 | -31.85 | -54.65 | -39.62 | |
| EV to operating cash flow | -30.22 | -39.28 | -59.26 | -41.9 | -45.13 | |
| EV to free cash flow | -26.93 | -38.02 | -34.89 | -41.39 | -45.36 | |
| Earnings yield | -0.06 | -0.04 | -0.1 | -0.03 | -0.03 | |
| Free cash flow yield | -0.05 | -0.03 | -0.03 | -0.03 | -0.03 | |
| Debt to equity | -166.36 | 2.94 | 33.21 | -16.34 | 16.14 | |
| Debt to assets | 0.78 | 0.6 | 0.72 | 0.8 | 0.72 | |
| Net debt to EBITDA | -7.24 | -4.8 | -5.51 | -5.61 | -4.79 | |
| Current ratio | 3.38 | 5.56 | 4.95 | 4.14 | 5.12 | |
| Interest coverage | -14.93 | -11.2 | -19.89 | -12.9 | -15 | |
| Income quality | 0.72 | 0.68 | 0.21 | 1.16 | 0.79 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.65 | 2.23 | 1.82 | 1.29 | 1.31 | |
| Research and developement to revenue | 0.88 | 0.9 | 0.39 | 0.47 | 0.39 | |
| Intangibles to total assets | 0.35 | 0.27 | 0.18 | 0.2 | 0.18 | |
| Capex to operating cash flow | 0.12 | 0.03 | 0.7 | 0.01 | 0 | |
| Capex to revenue | -0.19 | -0.07 | -0.42 | -0.02 | 0 | |
| Capex to depreciation | -0.82 | -0.22 | -1.15 | -0.13 | 0.08 | |
| Stock based compensation to revenue | 0.33 | 0.62 | 0.21 | 0.27 | 0.27 | |
| Graham number | 0.86 | 7.3 | 2.53 | 2.45 | 2.41 | |
| ROIC | -0.12 | -0.13 | -0.16 | -0.14 | -0.13 | |
| Return on tangible assets | -0.17 | -0.16 | -0.3 | -0.15 | -0.14 | |
| Graham Net | -4.56 | -2.35 | -2.63 | -3.39 | -2.64 | |
| Working capital | 183.72M | 340.86M | 299.05M | 245.04M | 304.87M | |
| Tangible asset value | -196.62M | -44.12M | -91.58M | -135.07M | -78.85M | |
| Net current asset value | -303.57M | -150.28M | -194.57M | -251.45M | -191.8M | |
| Invested capital | -166.36 | 2.94 | 33.21 | -16.34 | 16.14 | |
| Average receivables | 5.03M | 8.66M | 11.54M | 13.36M | 16.21M | |
| Average payables | 11.65M | 7.01M | 2.65M | 8.77M | 10.67M | |
| Average inventory | 12.13M | 15.39M | 17.75M | 23.05M | 31.11M | |
| Days sales outstanding | 17.73 | 36.39 | 20.44 | 28.05 | 26.39 | |
| Days payables outstanding | 125.43 | 6.24 | 17.4 | 72.33 | 35.25 | |
| Days of inventory on hand | 128.53 | 144 | 70.14 | 154.58 | 145.51 | |
| Receivables turnover | 5.07 | 2.47 | 4.4 | 3.21 | 3.41 | |
| Payables turnover | 0.72 | 14.43 | 5.17 | 1.24 | 2.55 | |
| Inventory turnover | 0.7 | 0.62 | 1.28 | 0.58 | 0.62 | |
| ROE | 23.37 | -0.58 | -11.47 | 2.48 | -2.51 | |
| Capex per share | -0.08 | -0.03 | -0.26 | -0.01 | 0 |
RVNC Frequently Asked Questions
What is Revance Therapeutics, Inc. stock symbol ?
Revance Therapeutics, Inc. is a US stock , located in Nashville of Tn and trading under the symbol RVNC
Is Revance Therapeutics, Inc. buy or a sell ?
4 stock analysts have 4 predictions with a medium analyst target price of $33.5. The lowest prediction is $24 and the highest is $38
What is RVNC stock prediction ?
With a median analyst target price of $35, 1 stock analysts have made 1 forecasts in last 90 days. $35 is the lowest and $35 is the greatest projection.
What is Revance Therapeutics, Inc. stock quote today ?
Revance Therapeutics, Inc. stock price is $11.75 today.
Is Revance Therapeutics, Inc. stock public?
Yes, Revance Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.74M
- Market Capitalization 1.14B
- Employee 534
- CEO Mr. Mark J. Foley
- Headquarters Nashville,TN,US
- IPO Date 2014-02-06
-
Website
https://www.revance.com 
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
